• Protocols

• ACCL2031

  OPEN TO ACCRUAL

  Ph3 randomized,placebo controlled trial with Mematine for Neurocognitive Protection
  
  

• ACNS1723

  OPEN TO ACCRUAL

  Phase 2 Dabrafenib and Trametinib after Local RT in Newly DX BRAFV600 Mutant HGG
  
  

• ACNS1821

  OPEN TO ACCRUAL

  Phase 1/2 Selinexor (KPT-330) and RT for Newly Dx DIPG and HGG
  
  

• ACNS1831

  OPEN TO ACCRUAL

  Phase 3 Rand Selumetinib vs. Carbo/Vinc in Newly Dx or Previously Untreated NF1 LGG
  
  

• ACNS1833

  OPEN TO ACCRUAL

  Phase 3 Rand Selumetinib vs. Carbo/Vinc in Newly Dx or Previously Untreated Non-BRAFV600E andNF1 LGG
  
  

• ACNS1931

  OPEN TO ACCRUAL

  Phase 3 study of Selumetinib vs Selumetinib/Vinblastine for non-NF1 recurrent/progressive LGG
  
  

• ACNS2021

  OPEN TO ACCRUAL

  Phase 2 Chemo followed by WVSC Irradiation for patients with NGGCT
  
  

• APEC1621SC

  OPEN TO ACCRUAL

  APEC1621_Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
  
  

• UW23096

  OPEN TO ACCRUAL

  Study of CLR131 in Children/AYA with Brain Tumors (Part B)